Genmab A/S

Forecast & Rating12 analysts currently cover Genmab A/S, with about 91.7% giving a positive rating — meaning they expect the stock to rise. The average price target is $44.13, about 20.4% upside from the current price of $36.65. Price targets range from $33.50 to $58.00 — a wide spread, showing clear disagreement over just how much Genmab A/S can rise. Historically, about 56.3% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study Genmab A/S closely still see room for the stock to rise. Data as of Oct 7, 2026; for reference only and not investment advice.